Novacyt Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Novacyt hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-€0.39
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Little Excitement Around Novacyt S.A.'s (EPA:ALNOV) Earnings As Shares Take 25% Pounding

Sep 29

Novacyt's (EPA:ALNOV) Wonderful 999% Share Price Increase Shows How Capitalism Can Build Wealth

Mar 08

Is Novacyt S.A.'s(EPA:ALNOV) Recent Stock Performance Tethered To Its Strong Fundamentals?

Jan 22

Calculating The Intrinsic Value Of Novacyt S.A. (EPA:ALNOV)

Dec 15

We're Not Counting On Novacyt (EPA:ALNOV) To Sustain Its Statutory Profitability

Nov 19

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ALNOV in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ALNOV gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Novacyt Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von ALNOV im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (ALNOV)	n/a
Untere 25 % des Marktes (FR)	1.9%
Markt Top 25 % (FR)	5.6%
Branchendurchschnitt (Biotechs)	1.8%
Analystenprognose in 3 Jahren (ALNOV)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ALNOV im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von ALNOV im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ALNOV, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ALNOV keine Ausschüttungen gemeldet hat.

Novacyt Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Revenues Working Against Novacyt S.A.'s (EPA:ALNOV) Share Price

New major risk - Share price stability

Novacyt S.A., Annual General Meeting, Jun 26, 2024

Novacyt S.A. to Report Fiscal Year 2023 Results on May 30, 2024

Less than half of directors are independent

Novacyt S.A. Notes DHSC Application for Summary Judgment Dismissed

New minor risk - Financial data availability

Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024

New minor risk - Share price stability

Is Novacyt (EPA:ALNOV) In A Good Position To Deliver On Growth Plans?

First half 2023 earnings released: UK£0.12 loss per share (vs UK£0.071 loss in 1H 2022)

New major risk - Revenue and earnings growth

Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023

Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023

We're Keeping An Eye On Novacyt's (EPA:ALNOV) Cash Burn Rate

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Full year 2022 earnings released: UK£0.31 loss per share (vs UK£0.14 loss in FY 2021)

Now 23% undervalued after recent price drop

Novacyt S.A. to Report Fiscal Year 2022 Results on Apr 24, 2023

Estimating The Fair Value Of Novacyt S.A. (EPA:ALNOV)

Now 21% undervalued after recent price drop

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Novacyt Announces Step Down of David Allmond as Member of the Board

Novacyt Announces Approval of genesig® SARS-CoV-2 Winterplex® 3 Gene Assay Panel in the UK Under CTDA Legislation

First half 2022 earnings released: UK£0.07 loss per share (vs UK£0.18 loss in 1H 2021)

Novacyt S.A. Provides Group Financial Guidance for the Third Quarter and Year-To-Date Ended September 2022 and Fourth Quarter of 2022

Novacyt S.A. to Report First Half, 2022 Results on Sep 29, 2022

Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays

Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay

Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK

Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeypox Assay in Response to the Recent Outbreak of the Virus in Non-Endemic Countries

Novacyt S.A., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings released: UK£0.14 loss per share (vs UK£1.94 profit in FY 2020)

Novacyt S.A. Provides Update on DHSC Dispute

Novacyt Announces Approval of COVID-19 Test Under CTDA Legislation

CEO & Director recently bought €121k worth of stock

With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

Novacyt S.A. Announces Approval of the First Direct-To-PCR Covid-19 Test in the UK Under CTDA Legislation

Novacyt S.A. to Report Fiscal Year 2021 Results on Apr 25, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

Investor sentiment improved over the past week

High number of new directors

Investor sentiment improved over the past week

Little Excitement Around Novacyt S.A.'s (EPA:ALNOV) Earnings As Shares Take 25% Pounding

Investor sentiment improved over the past week

Novacyt S.A. Reiterate Revenue Guidance for the Full Year

Full year 2020 earnings released: EPS UK£1.94 (vs UK£0.072 loss in FY 2019)

Novacyt S.A. Provides Sales Guidance for the Full Year 2021

Novacyt S.A. Announces the Launch of Two New Polymerase Chain Reaction Assays, Expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 Variant Detection Portfolios

Novacyt S.A. Announces Launch of VersaLab™ Portable

Investor sentiment deteriorated over the past week

Price target decreased to €4.90

Novacyt S.A. Announces Inclusion of SNPsig SARS-CoV-2 PCR Genotyping Portfolio in the NHS England Framework and Expansion of SNPsig Product Range

Investor sentiment improved over the past week

Novacyt S.A. Provides Earnings Guidance for the Year 2021

Investor sentiment deteriorated over the past week

Novacyt's (EPA:ALNOV) Wonderful 999% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: €7.93

Investor sentiment deteriorated over the past week

Novacyt S.A. Announces Launch of PCR Genotyping Assay Portfolio to Detect Covid-19 Variants

New 90-day high: €13.24

Is Novacyt S.A.'s(EPA:ALNOV) Recent Stock Performance Tethered To Its Strong Fundamentals?

Investor sentiment improved over the past week

Novacyt S.A. Announces Board Changes

Novacyt S.A. Appoints James McCarthy as Chief Financial Officer

Calculating The Intrinsic Value Of Novacyt S.A. (EPA:ALNOV)

Novacyt S.A. Announces the Development of Three Tests for New Strains of COVID-19 and Avian Influenza

Market bids up stock over the past week

We're Not Counting On Novacyt (EPA:ALNOV) To Sustain Its Statutory Profitability

CEO & Director recently bought €558k worth of stock

Market pulls back on stock over the past week

Market pulls back on stock over the past week